Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...

Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer p...

Alkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously d...

The product is used in the treatment of breast cancer and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Me...

"In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial. Th...

Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma,...

Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and met...

Quoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending...

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.

Biocon shares tanked 5.9 per cent to Rs 328.80 at the close on the BSE on Wednesday.

The USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.

CCI’s action is in response to a complaint filed by Mylan and Biocon, who have together developed biosimilar version of Roche’s blockbuster...

The court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...

This is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."

Drug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.